- $32.60m
- -$16.45m
- $11.00m
Annual income statement for Bioatla, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.429 | 0.25 | 0 | 0 | 11 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.4 | 96 | 108 | 130 | 84.9 |
| Operating Profit | -33 | -95.8 | -108 | -130 | -73.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -35.9 | -95.4 | -106 | -123 | -69.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -35.9 | -95.4 | -106 | -123 | -69.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -35.9 | -95.4 | -106 | -123 | -69.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -35.9 | -95.4 | -106 | -123 | -69.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.03 | -2.78 | -2.74 | -2.58 | -1.44 |
| Dividends per Share |